)
)
)
Nonhuman primate studies have recently shown that Maxwell Biosciences has developed a breakthrough innovation to address humanity’s most serious, unmet infectious disease threats—one medicine for all pathogenic bacteria and fungi and biofilm formations. Maxwell's DARPA-seeded "Synthetic Immune System" technology is backed by over $63M in government grants and investor financing. The technology has scientific validation in over 500 peer-reviewed published studies and 7 US military Collaborative Research and Development Agreements. Maxwell received very encouraging Pre-IND feedback ahead of its FDA IND submission, anticipated in 2026. Maxwell's novel compounds are protected by a series of patents, and are likely to achieve Qualified Infectious Disease Product status which conveys Fast Track and 12 years of market exclusivity. Maxwell is creating a library of drug candidates designed to mimic natural immunity and extend health span—with $300+B in annual market potential within 10 years.
Year Founded
2016
Next catalyst (value inflection) update
potential $100MM grant from government of India; human trials
Expected time of next catalyst update
grant should be finalized Q1 2026; human trials may begin in 2026
City
Austin
Country
United States
Company CEO or top company official
J. "Scotch" McClure
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
MXB-22,510 (LL-37 peptide mimic) nasal spray for Chronic rhinosinusitis (CRS) Maxwell is a platform biopharma company that can mimic any peptide in the human innate immune system, in a more stable form.
Number of Unlicensed Products
multiple
Therapeutic Area
Infectious Diseases
Website
https://maxwellbiosciences.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
